SCPH (scPharmaceuticals, Inc.) Market Value to Book Value Ratio

Official company branding of scpharmaceuticals.com (SCPH)

This chart shows shares of scPharmaceuticals Inc. (SCPH), a recognized innovator in heart failure therapy offering convenient home infusion methods. The stability of pump and solution production is ensured by the functional equipment of partners and strict sterility control. The current metric stands at -14.12, while business growth relies on recognition by insurance companies and the availability of systems for non-hospital use.

SCPH scpharmaceuticals.com: Market Value to Book Value in the range 07/04/2022 - 10/18/2025
Original product of scpharmaceuticals.com

The implementation of ESG standards in the production of infusion systems at scPharmaceuticals Inc. (SCPH) enhances resource management efficiency, which directly impacts the net asset value. An analysis of the company's P/B ratio allows for a comparison between the current market price and the book value, revealing the actual business discount and helping investors distinguish an undervalued asset from a value trap amidst market volatility.

Main competitors

Market Capitalization to Book Value Ratio Haleon plc HLN|KVUE (kenvue.com) - Market Value to Book Value|Market Value to Book Value Ratio Verona Pharma VRNA|Market Capitalization to Net Assets Jyong Biotech Limited|Ligand Pharma (LGND) - Market Capitalization to Book Value Ratio|Market Value to Book Value Amneal Corp (AMRX)|Market Capitalization to Book Value Ratio PRGO (Perrigo Company plc)|alvotech.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Liquidia (LQDA)|GLPG: Market Value to Book Value|ANIP (ANI Pharma) - Market Value to Book Value Ratio|Afrezza (MNKD) - Market Cap to Net Assets Ratio|AMPH (Amphastar Pharmaceuticals) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio pacira.com (PCRX)|ARS Pharmaceuticals, Inc. (SPRY) - Market Cap to Net Assets Ratio|Market Value to Book Value TBPH (Theravance Biopharma Inc)|AQST: Market Value to Book Value Ratio|TECX - Market-to-Book Ratio|Market Cap to Net Assets Ratio Tonix Pharmaceuticals TNXP|SXTC - Market Cap to Book Value Multiple|Market Capitalization to Book Value Ratio eupraxiapharma.com EPRX|BioHarvest Sciences, Inc. (BHST) - Market Value to Book Value|Market Capitalization to Book Value Ratio EXOZ (Invizyne Technologies, Inc.)|Market-to-Book Ratio ORMP|Entera Bio Ltd. (ENTX) - Market Value to Book Value Ratio|Market Value to Book Value HYFT (ipatherapeutics.com)|Market Value to Book Value Ratio ABVC|Market Capitalization to Book Value Cumberland Pharmaceuticals Inc CPIX|QNTM: Market Capitalization to Book Value Ratio|FGEN: Market Cap to Net Assets Ratio|Market Value to Book Value Ratio Telomir Pharmaceuticals (TELO)|Rani Therapeutics Holdings, Inc. (RANI) - Market Capitalization to Net Assets|SNYR - Market Capitalization to Book Value Ratio|Market Value to Book Value Rallybio Corp.|Market Capitalization to Book Value Ratio LEXX|Market Capitalization to Book Value Ratio PULM (Pulmatrix Corporation)|Market Value to Book Value Ratio Pheton Holdings|Aptorum Group Ltd - Market Value to Book Value|LYRA: Market Value to Book Value Ratio|IBO - Market Cap to Net Assets Ratio|TNFA: Market Capitalization to Book Value Ratio|cbdMD (YCBD) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio PRFX|Market Cap to Net Assets Ratio Auris Medical|Lipella Pharmaceuticals, Inc. - Market Capitalization to Book Value Ratio|Market-to-Book Ratio OptiNose Inc OPTN|Market Cap to Net Assets Ratio PIRS (Pieris)|PROC - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio Petros Pharmaceuticals PTPI|QLI - Market Cap to Book Value Multiple|ACELYRIN - Market Capitalization to Book Value Ratio|TFF Pharmaceuticals Inc. (TFFP) - Market Capitalization to Book Value